Medical technology company Hologic Inc (Nasdaq:HOLX) stated on Friday that it expects to collect total revenues of approximately USD850.5m for first fiscal quarter ended 28 December 2019.
This marks a growth of 2.4% over the prior year period, or 2.8% in constant currency.
Excluding acquisitions and divestitures, the revenue rises 4.1%, 4.6% in constant currency.
Hologic said the preliminary results are compared to the most recent guidance range of USD835 to USD850m for its first fiscal quarter ended 28 December 2019.
Additionally, the company's board of has authorised a new, USD500m share repurchase plan that will go into effect at the start of the fiscal third quarter, when the existing authorization will expire.
The company added that it is taking part in the 38th Annual JP Morgan Healthcare Conference, which began on 13 January 2020.
Abbott to pay 385th consecutive quarterly dividend of USD0.36 per share
Abbott announces quarterly common dividend
Lysogene reports cash and cash equivalent of EUR26.5m as of 31 December 2019
GC Pharma announces 2019 unaudited results
Inotrem Expands series B Financing to EUR 58m
Molina Healthcare reports increased net income of USD737m for 2019